Last reviewed · How we verify
MEDI4736 monotherapy — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
MEDI4736 monotherapy (MEDI4736 monotherapy) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MEDI4736 monotherapy TARGET | MEDI4736 monotherapy | AstraZeneca | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MEDI4736 monotherapy CI watch — RSS
- MEDI4736 monotherapy CI watch — Atom
- MEDI4736 monotherapy CI watch — JSON
- MEDI4736 monotherapy alone — RSS
Cite this brief
Drug Landscape (2026). MEDI4736 monotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/medi4736-monotherapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing